1.For the molecular subtyping detection of patients with cytogenetically normal precursor B-cell ALL (BCP-ALL).
2.Most ALL patients exhibit recurrent molecular genetic abnormalities, which are of significant importance for guiding the diagnosis, classification, and treatment of ALL patients.